Category - Markets

H.C. Wainwright launched coverage of BioTime (NYSE American:BTX) with a “buy” rating and $4 price target. The stock closed at $1.15 on Feb. 20. Analyst Joseph Pantginis writes that BioTime was originally focused on...

Roth Capital Partners launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $14 price target. The stock closed at $4.84 on Feb. 19. “Arcturus is a hidden gem in a sea of RNA medicines...

H.C. Wainwright initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $36 price target. The stock closed at $24.03 on Feb. 19. Analyst Debjit Chattopadhyay writes that Homology’s platform...

Roth Capital Partners initiated coverage of Chiasma (NASDAQ:CHMA) with a “buy” rating and $16 price target. The stock closed at $3.87 on Feb. 15. “With two Phase 3 readouts on the horizon, Chiasma is a fallen angel...

BTIG launched coverage of Synlogic (NASDAQ:SYBX) with a “buy” rating and $22 price target. The stock closed at $9.56 on Feb. 12. “We view Synlogic’s approach to correct inborn errors of metabolism via addition of key...

BTIG launched coverage of Geron (NASDAQ:GERN) with a “buy” rating and $4 price target. The stock closed at $1.31 on Feb. 12. Geron is focused on development of imetelstat, a telomerase inhibitor active in the treatment...

H.C. Wainwright initiated coverage of France-based Inventiva (PSE:IVA) with a “buy” rating and price target of €19. The stock closed at €6.40 on Feb. 12. Inventiva was spun out of Abbott Labs in 2012 and is focused on...

BTIG initiated coverage of MEI Pharma (NASDAQ:MEIP) with a “buy” rating and price target of $5.50. The stock closed at $2.96 on Feb. 12. “MEI Pharma is developing in-licensed drugs that we see as having good chances of...

Stifel initiated coverage of Ra Pharmaceuticals (NASDAQ:RARX) with a “buy” rating and $55 price target. The stock closed at $19.87 on Feb. 7. Ra Pharma uses a proprietary peptide chemistry platform to develop...

SVB Leerink downgraded Solid Biosciences (NASDAQ:SLDB) to “market perform” from “outperform” and slashed its price target to $8 from $50 after the company reported disappointing Phase 1/2 data from its experimental gene...